Halozyme Therapeutics (NASDAQ:HALO) Director Sells 7,304 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $1.09 during midday trading on Tuesday, reaching $78.27. The company’s stock had a trading volume of 1,944,476 shares, compared to its average volume of 1,802,008. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock has a fifty day moving average of $68.64 and a 200 day moving average of $69.01. Halozyme Therapeutics, Inc. has a twelve month low of $51.78 and a twelve month high of $82.22. The firm has a market capitalization of $9.28 billion, a PE ratio of 28.15, a P/E/G ratio of 0.31 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the firm posted $1.11 earnings per share. The firm’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Western Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth approximately $229,000. Alpine Woods Capital Investors LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at $281,000. Glenmede Trust Co. NA lifted its holdings in Halozyme Therapeutics by 22.4% in the 1st quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company’s stock valued at $9,482,000 after purchasing an additional 26,851 shares in the last quarter. Argent Capital Management LLC boosted its stake in Halozyme Therapeutics by 52.2% during the 1st quarter. Argent Capital Management LLC now owns 9,054 shares of the biopharmaceutical company’s stock worth $585,000 after purchasing an additional 3,104 shares during the last quarter. Finally, BankChampaign National Association acquired a new stake in Halozyme Therapeutics during the 1st quarter worth $228,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HALO. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.